Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
|Articles|May 1, 2007
- Volume 0 0
MYLAN BARRED FROM SELLING GENERIC TOPAMAX
Advertisement
A federal judge in NewJersey issued an injunctionpermanently barringMylan Pharmaceuticalsfrom selling generic topiramatetablets and capsulesin the United Statesbefore September 26,2008, the expiration dateof the patent for TOPAMAX(topiramate) heldby Ortho-McNeil NeurologicsInc. Mylan hadchallenged the validity ofthat patent and filed anabbreviated new drugapplication to market ageneric version of theepilepsy drug. The brandedmanufacturer counteredwith a patentinfringement complaintagainst Mylan and obtaineda preliminary injunctionagainst the genericfirm last fall.
Articles in this issue
over 19 years ago
can you READ these Rxs?over 19 years ago
compounding HOTLINEover 19 years ago
Pseudoephedrine Logs Need Constant Tendingover 19 years ago
Another Federal Court Rejects a Drug Importation Planover 19 years ago
Home Infusion Therapy Gets Patients Out of the Hospitalover 19 years ago
RESPy AWARD: Teamwork Is the Thread That Bindsover 19 years ago
Child-resistant Does Not Mean Childproofover 19 years ago
ccpa SPEAKS OUT: CCPA Works to Improve Medicare Part Dover 19 years ago
Genetic Testing: Remarkable Resource or Invasion of Privacy?over 19 years ago
case STUDIESAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
4
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
5